Among these drugs, the most important one is Venetoclax and its application in CLL patients with 17p deletion, resulting in a loss of the TP53 gene, enabling the direct apoptotic realization without the presence of p53 [81,184]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.